Primary Analysis of MOUNTAINEER: A Phase 2 Study of Tucatinib and Trastuzumab for HER2-positive mCRC

Jul 28, 2022

Tanios Bekaii-Saab, MD

Video

Dr Tanios Bekaii-Saab reviews data from the MOUNTAINEER trial on combination tucatinib/trastuzumab in patients with HER2-positive metastatic colorectal cancer.

Related Videos

Marwan G. Fakih, MD

Howard S. Hochster, MD

Daneng Li, MD

Arvind Dasari, MD, MS, an expert on colorectal cancer

Megan Hitchins, PhD

Whitney S. Graybill, MD, MS, an expert on ovarian cancer

Marwan G. Fakih, MD

Scott Kopetz, MD, PhD, FACP

Related Content

Efforts Are Underway to Refine Prognostic Value of ctDNA to Guide Adjuvant Therapy in CRC

September 22nd 2023

FDA Approval Insights: Tucatinib and Trastuzumab in HER2+ mCRC

February 6th 2023

Novel mRNA Biomarker Integration Boosts Sensitivity, Specificity of ColoAlert in Detecting CRC

September 13th 2023

Research Reflections: Subbiah Reviews Striking ASCO 2022 Data Across Oncology

August 1st 2022

Trifluridine/Tipiracil Plus Bevacizumab Provides Potential First-Line Alternative to Bevacizumab/Capecitabine in mCRC

August 30th 2023

Postoperative ctDNA Provides Prognostic Value for DFS Outcomes in CRC

August 26th 2023

Efforts Are Underway to Refine Prognostic Value of ctDNA to Guide Adjuvant Therapy in CRC

September 22nd 2023

FDA Approval Insights: Tucatinib and Trastuzumab in HER2+ mCRC

February 6th 2023

Novel mRNA Biomarker Integration Boosts Sensitivity, Specificity of ColoAlert in Detecting CRC

September 13th 2023

Research Reflections: Subbiah Reviews Striking ASCO 2022 Data Across Oncology

August 1st 2022

Trifluridine/Tipiracil Plus Bevacizumab Provides Potential First-Line Alternative to Bevacizumab/Capecitabine in mCRC

August 30th 2023

Postoperative ctDNA Provides Prognostic Value for DFS Outcomes in CRC

August 26th 2023

Efforts Are Underway to Refine Prognostic Value of ctDNA to Guide Adjuvant Therapy in CRC

September 22nd 2023

FDA Approval Insights: Tucatinib and Trastuzumab in HER2+ mCRC

February 6th 2023

Novel mRNA Biomarker Integration Boosts Sensitivity, Specificity of ColoAlert in Detecting CRC

September 13th 2023

Research Reflections: Subbiah Reviews Striking ASCO 2022 Data Across Oncology

August 1st 2022

Trifluridine/Tipiracil Plus Bevacizumab Provides Potential First-Line Alternative to Bevacizumab/Capecitabine in mCRC

August 30th 2023

Postoperative ctDNA Provides Prognostic Value for DFS Outcomes in CRC

August 26th 2023

Related Content

Efforts Are Underway to Refine Prognostic Value of ctDNA to Guide Adjuvant Therapy in CRC

Efforts Are Underway to Refine Prognostic Value of ctDNA to Guide Adjuvant Therapy in CRC

September 22nd 2023

John H. Strickler, MD

FDA Approval Insights: Tucatinib and Trastuzumab in HER2+ mCRC

February 6th 2023

Colorectal Cancer © stock.adobe.com

Novel mRNA Biomarker Integration Boosts Sensitivity, Specificity of ColoAlert in Detecting CRC

September 13th 2023

Research Reflections: Subbiah Reviews Striking ASCO 2022 Data Across Oncology

Research Reflections: Subbiah Reviews Striking ASCO 2022 Data Across Oncology

August 1st 2022

Thierry André, MD

Trifluridine/Tipiracil Plus Bevacizumab Provides Potential First-Line Alternative to Bevacizumab/Capecitabine in mCRC

August 30th 2023

Jun Watanabe, MD, PhD

Postoperative ctDNA Provides Prognostic Value for DFS Outcomes in CRC

August 26th 2023

Latest Conference Coverage

Smoldering Multiple Myeloma Management Hinges on the Debate Between Treatment and Observation

Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis

Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment

First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.